Reduction in the level of immunotitratable dopamine beta-hydroxylase after chronic administration of L-dopa or alpha-methyldopa.
D000311:Adrenal Glands / Q000187:drug effects / Q000201:enzymology*; D000596:Amino Acids; D000818:Animals; D002262:Carboxy-Lyases / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D007118:Immunoassay; D005779:Immunodiffusion; D007700:Kinetics; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D008750:Methyldopa / Q000494:pharmacology*; D009206:Myocardium / Q000201:enzymology*; D051381:Rats
D000596:Amino Acids; D007980:Levodopa; D008750:Methyldopa; D007770:L-Lactate Dehydrogenase; D004299:Dopamine beta-Hydroxylase; D002262:Carboxy-Lyases